



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-772)

In re Application of:)
)
Somberg et al.)
) Group Art Unit: 1651
Serial No.: 10/655,878)
) Examiner: C. Petersen
Filed: September 5, 2003)
) Confirmation No.: 6857
For: Method for Detecting Transferase)
Enzymatic Activity)
)

TRANSMITTAL LETTER

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. We are transmitting herewith the attached papers for the above-identified patent application:

- ☒ Fourth Supplemental Information Disclosure Statement (2 sheets)
- ☒ Fourth Supplemental Information Disclosure Statement Form PTO/SB/08 (2 sheets)
- ☒ Copy of 2 cited references
- ☒ Return Receipt Postcard

2. **GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES:** No fee is due at this time. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

3. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 16 day of May, 2006.

Respectfully submitted,

Emily Miao
Registration No. 35,285

Date:

May 16, 2006



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-772)

In re Application of:)
)
Somberg et al.)
) Group Art Unit: 1651
Serial No.: 10/655,878)
) Examiner: C. Petersen
Filed: September 5, 2003)
) Confirmation No.: 6857
For: Method for Detecting Transferase)
Enzymatic Activity)
)

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto are Forms PTO/SB/08a and PTO/SB/08b. This document contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1	US 6,911,319	6/28/05	Crouch et al.
2	WO 02/48390	6/20/02	Lumitech UK Ltd.
3	KAPOOR ET AL., Pyruvate Kinase of Neurospora crassa: effect of various ligands on the rate of inactivation by protein denaturants, Canadian Journal of Microbiology, 1972, pp. 1221-1232, Vol. 18, NRC Research Press - National Research Council of Canada, Ottawa, Canada.		


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Forms PTO/SB/08a and PTO/SB08b) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: May 16, 2006

Respectfully submitted,



Emily Miao
Registration No. 35,285

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 913-0001
Facsimile: (312) 913-0002

Substitute for form 1449A/PTO

**4th SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT**

(Use as many sheets as necessary)


Sheet

1

2

Complete if Known

Application Number	10/655,878
Filing Date	September 5, 2003
First Named Inventor	Somberg
Art Unit	1651
Examiner Name	C. Petersen
Attorney Docket Number	03-772

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US- 6,911,319	6/28/05	Crouch et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)				
	2	WO 02/48390	6/20/02	Lumitech UK Ltd.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO 4th SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/655,878		
		Filing Date	September 5, 2003		
		First Named Inventor	Somberg		
		Art Unit	1651		
		Examiner Name	C. Petersen		
Sheet	2	of	2	Attorney Docket Number	03-772

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	KAPOOR ET AL., Pyruvate Kinase of Neurospora crassa: effect of various ligands on the rate of inactivation by protein denaturants, Canadian Journal of Microbiology, 1972, pp. 1221-1232, Vol. 18, NRC Research Press - National Research Council of Canada, Ottawa, Canada.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.